SBC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SBC Medical Group Holdings Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently oversold, but technical indicators and recent news suggest caution. The secondary public offering and bearish technical trends outweigh the positive analyst rating and improved financial performance. It is better to wait for more favorable conditions before investing.
The stock is in a bearish trend with MACD negatively expanding, RSI indicating oversold conditions at 17.589, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at $3.482 and $3.197, while resistance levels are at $4.407 and $4.692. The stock is trading below its pivot point of $3.945.
Analyst BTIG initiated coverage with a Buy rating and a price target of $8, citing numerous growth prospects and a valuation discount compared to peers.
Financial performance shows a significant YoY increase in Net Income (+117.16%) and EPS (+133.33%) in Q4 2025.
Secondary public offering of 3.1 million shares priced at $3.25, which could dilute existing shareholder value.
Revenue dropped by -10.93% YoY in Q4 2025, and gross margin declined by -4.12%.
Bearish technical indicators and lack of significant trading trends from hedge funds or insiders.
In Q4 2025, SBC reported a revenue decline of -10.93% YoY to $39,566,706. However, net income increased significantly by 117.16% YoY to $14,200,291, and EPS rose by 133.33% YoY to $0.14. Gross margin decreased slightly to 73.11%, down -4.12% YoY.
BTIG analyst Sam Eiber initiated coverage with a Buy rating and a price target of $8, highlighting SBC as a leading aesthetic medical group in Japan with strong growth prospects and a valuation discount compared to peers.
